🟢 92/100

This product looks safe

  • Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)
  • 40% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 250mg is 7.1× the Tolerable Upper Intake Level (35mg)

Label Data

3 Capsule(s) Serving Size
60 Servings
Other Combinations Product Type
40% Evidence Coverage

Supplement Facts — Evidence Check

250 mg (1250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 7.1× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 250mg UL 35mg
Policosanol
10 mg
Guggul Gum Extract
375 mg
✅ Within RDA (0.2× RDA of 15 mg) 📚 177 studies (Tier A: 3, B: 90)
RDA 15mg This product: 3mg UL 1000mg
Phytosterol Complex
400 mg

Other Ingredients

Gelatin Microcrystalline Cellulose Silicon Dioxide Magnesium Silicate Magnesium Stearate

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Take three capsules two times daily with meals or as directed by your healthcare professional.

⚠️ Warnings & Precautions

Caution: Due to potential blood-thinning effects of policosanol, please consult with your physician before taking this product if you take Coumadin(R) (Warfarin) or other blood thinners. Do not use this product if you are pregnant or nursing.

KEEP OUT OF REACH OF CHILDREN.

Additional Information

For Healthy Cholesterol*

SCIENTIFICALLY FORMULATED DOCTOR APPROVED

STORE IN A COOL, DRY PLACE.

This product is manufactured in a NSF GMP registered facility.

Contains the World's Finest Ingredients.

MADE IN U.S.A.

300-TUCFC-8

Product Details

DSLD Entry Date 2012-12-21
Product Type Other Combinations
Form Capsule
Brand True Health
DSLD ID 16742
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →